Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

Stanley T. Crooke, Brenda F. Baker, Shuting Xia, Rosie Z. Yu, Nicholas J. Viney, Yanfeng Wang, Sotirios Tsimikas, and Richard S. Geary

Advances in medicinal chemistry have produced new chemical classes of antisense oligonucleotides (ASOs) with enhanced therapeutic properties. Conjugation of the triantennary *N*-acetylgalactosamine (GalNAc₃) moiety to the extensively characterized phosphorothioate (PS)-modified 2'-*O*-methoxyethyl (2'MOE) ASO exemplifies such an advance. This structure-activity optimized moiety effects receptor-mediated uptake of the ASO prodrug through the asialoglycoprotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available from randomized placebo-controlled dose-ranging studies of this chemical class of ASOs administered systemically to healthy human volunteers. First, we compare the pharmacokinetic and pharmacodynamic profiles of a subset of the GalNAc₃-conjugated PS-modified 2'MOE ASOs to the parent PS-modified 2'MOE ASOs for which plasma analytes are available. We then evaluate the safety profile of the full set of GalNAc₃-conjugated PS-modified 2'MOE ASO conjugates by the incidence of signals in standardized laboratory tests and by the mean laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED₅₀ for the GalNAc₃-conjugated PS-modified 2'MOE ASO subset ranges from 4 to 10 mg/week, up to 30-fold more potent than the parent PS-modified 2'MOE ASO. No GalNAc₃-conjugated PS-modified 2'MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens. The increase in potency supports an increase in the safety margin for this new chemical class of ASOs now under broad investigation in the clinic. Although the total exposure is limited in the initial phase 1 trials, ongoing and future investigations in patient populations will support evaluation of the effects of long-term exposure.

Keywords: antisense, oligonucleotide, assessment, clinical trials, triantennary *N*-acetylgalactosamine

Introduction

TODAY, FIVE ANTISENSE OLIGONUCLEOTIDES (ASOs) have been commercialized and one is under review, with indications as diverse as spinal muscular atrophy (SMA) to hereditary transthyretin amyloidosis (hATTR). Scores of other ASOs are progressing in development, representing a number of different chemical and mechanistic classes [1]. ASOs have been administered to humans by intravitreal, intrathecal, intravenous, subcutaneous (SC), and intramuscular injections, orally, and by inhalation and enema [2]. Thus, the potential of antisense technology is being realized while the technology continues to advance and produce steadily better performing agents [3].

Therapeutic oligonucleotides consist of three key elements, the hydrophobic nucleobase, a carbohydrate or modified carbohydrate, and a phosphate or phosphate analog. The nucleobase identifies target sites in RNAs through Watson-Crick hybridization. Optimal affinity and selectivity are conferred by 16–20 nucleotides [4]. In principle, 11–12 nucleotides should confer acceptable selectivity, but even using high RNA affinity oligonucleotides, the affinity is such that potency is inadequate *in vivo*, for review see Crooke *et al.* [5]. The carbohydrate is usually a deoxy ribose, a ribose, or a modified ribose. Substitutions at the 2'-position of the ribose alter the structure of the sugar and thus can be used to enhance affinity for target RNA sequences and hence potency. Modified sugars can also contribute a substantial increase in

Ionis Pharmaceuticals, Inc., Carlsbad, California.

© Stanley T. Crooke, et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

resistance to the endonucleases that perform the first step in the metabolism of oligonucleotides. The most frequently used modified sugar residues are 2'-fluoro (2'F), 2'-O-methoxyethyl (2'MOE), or constrained sugars such as "Locked nucleic acids" (LNAs) or constrained ethyl (cEt), for review see Refs. [1,3,6]. The phosphate or a modified phosphate is used to connect the nucleotides to form an oligonucleotide. The most commonly used phosphate analog is phosphorothioate (PS). Substitution of a nonbridging oxygen with a sulfur results in broader distribution of the phosphate charge and greater hydrophobicity. These changes enhance nuclease resistance and most importantly increase the promiscuity and affinity of interactions with proteins, for review see Levin *et al.* [7]. The neutral morpholino is also used, but has limited potency *in vivo*, for review see Refs. [1,3,8].

The nucleobase is critical for the potency and specificity of pharmacological effects. Carbohydrates that enhance potency and duration of effects, such as 2'MOE, cEt, or LNA, are used routinely. 2'F ribose is used extensively in small-interfering RNAs (siRNAs), but does not enhance nuclease resistance [1] and is associated with toxicities caused both by the intact oligonucleotide and one of the main degradates, 2'F ribose [9]. The PS moiety is the key determinant of distribution and the ability to cross membrane structures because of protein binding [7]. A minimum of 12 PS residues is sufficient to result in plasma protein binding, thus avoiding rapid excretion by the kidney [1]. The PS moiety also results in binding to proteins on the cell surface and in the cell, for review see Crooke *et al.* [10].

Double-stranded oligonucleotides, siRNAs, are highly hydrophilic and thus do not enter cells or organs without complex delivery systems, such as lipid nanoparticles, or conjugation of ligands that take advantage of high-capacity receptor systems, such as asialoglycoprotein receptors as is the case in hepatocytes for *N*-acetylgalactosamine (GalNAc), for review see Refs. [3,11,12]. In contrast, single-strand oligonucleotides (ASOs or single-stranded siRNAs) are amphipathic and thus can cross membranes without the need of formulations or transfection, for review see Refs. [1,2,13].

Of the chemical classes that have been studied, 2'MOE ASOs have been the most thoroughly evaluated [1,2]. Three 2'MOE ASOs have been commercialized, and one (volanesorsen) is under review in Europe, Canada, and the United States. Three, mipomersen, volanesorsen, and inotersen, are designed to exploit RNase H1-mediated RNA target reduction and are administered by weekly SC injection [14–16]. The fourth, nusinersen (Spinraza), is a fully 2'MOE-modified ASO designed to alter the splicing of a specific pre-mRNA and administered intrathecally every 4 months to treat patients with SMA [17–19].

The pharmacokinetics of PS-modified 2'MOE chimeric or "gapmer" ASOs have been extensively characterized in animals and humans. These ASOs are called chimeric or gapmer ASOs because they are designed to exploit RNase H1-mediated cleavage of RNA and thus have a central region (usually 8–10 nucleotides) of PS deoxynucleotides (DNA like) flanked by 2'MOE PS residues on the 5' and 3' poles, for review see Refs. [1,10,20]. Absorption and distribution are defined by the PS moieties and thus are similar for PS gapmers and fully 2'-modified PS ASO used to alter splicing or effect translation inhibition or polyadenylate site masking or upstream open-reading frame or translation inhibitory

structure-enhanced translation [5,21,22]. After SC dosing, absorption of these ASOs is nearly 100%. The absorption phase half-life is ~60 min in humans and the distribution half-life is 30–60 min, for review see Refs. [1,23]. The pharmacokinetics of these ASOs are remarkably consistent in all species tested [mice, rats, dogs, nonhuman primates (NHPs), and humans].

Plasma protein binding is critical to distribution and these drugs bind to a number of plasma proteins, but the main plasma repository is albumin. The dissociation constant (K_d) for albumin varies from species to species, the degree of lipidation of albumin, the method used to measure binding and, of course, the number of PSs, but for an ASO that has 19 PS residues, the K_d is 140–150 μ M. This binding is sufficient to prevent rapid renal clearance and yet the affinity is weak enough to support disproportionation between albumin and capillary, interstitial, and cell surface proteins, for review see Refs. [1,2]. These ASOs are widely distributed at lower doses to liver, kidney, fat cells, the spleen, and bone marrow [7,24]. At higher doses, the primary tissues saturate and these ASOs can then accumulate in secondary tissues [3,23]. Suborgan pharmacokinetics are well characterized in animals for the liver and kidney [25–27]. The liver accumulates ~20% of a total systemic dose achieving ~200–400 μ g/g liver in PS 2'MOE ASO concentration at therapeutic doses [28–30]. These ASOs distribute to all the major cell types in the liver with nonparenchymal cells accumulating most of the liver's ASO levels.

Elimination half-lives from all tissues including the liver are long, 2–4 weeks. Elimination is effected by endonuclease cleavage in the DNA gap for gapmers resulting in half molecules that may be further degraded by exonucleases. As these degradates have only eight to nine PS moieties, they are rapidly cleared by glomerular filtration [7,31,32]. These drugs do not interact with cytochrome p450 enzymes [33]. They do not bind to drug binding sites on albumin, so there are limited drug–drug interactions [34].

Because members of a chemical class share similar properties, we have constructed databases that integrate all safety and tolerability observations from toxicity studies in NHPs and all randomized double-blind placebo-controlled trials for each chemical class of ASOs we are developing. Although the potency of 2'MOE ASOs has increased compared with mipomersen because of more effective screening, the potency of more recently discovered 2'MOE ASOs are consistent with ED_{50s} of ~150–200 mg/week for targets in the liver [3,35]. Of course, the pharmacokinetic properties of this chemical class are also similar as discussed previously. Similarly, the safety and tolerability profiles have been characterized.

Three publications that summarize the analyses of the integrated safety database that include results from >2,600 subjects treated with 16 2'MOE ASOs systemically in 52 completed clinical trials have been published [36–38]. These publications established the clinical safety of the 2'MOE ASO and highlighted two adverse events, thrombocytopenia and exacerbation of renal dysfunction in patients with hATTR and thrombocytopenia in patients with familial chylomicronemia syndrome that seem to be the result of unique interactions between two different ASOs at doses of 300 mg/week in two unique patient populations. It is important to emphasize that only members of the same chemical

class share similar properties and that even what may seem minor chemical differences, for example, 2'MOE versus 2'-*O*-methyl (2'OMe), can greatly influence the behavior of ASOs. Therefore, the comments above refer strictly to the properties of members of the 2'MOE chemical class.

More recently, conjugation of triantennary *N*-acetyl-galactosamine (GalNAc₃) to 2'MOE ASOs has been shown to increase productive delivery of ASOs to the liver resulting in substantial increases in potency for hepatocyte produced target RNAs [1,39–44]. Today ten 2'MOE ASOs conjugated with a GalNAc₃ moiety are in development and 9 have completed at least a 4-week clinical trial in normal volunteers. In total, >600 subjects have been exposed to this chemical class with >200 subjects exposed for 6 months or longer. The purpose, therefore, of this publication is to provide an initial assessment of the performance GalNAc₃-conjugated 2'MOE ASOs after weekly or monthly SC dosing in healthy human volunteers. The experience in NHPs with this chemical class will be the subject of a separate report.

Materials and Methods

Clinical trial protocols were approved by the respective institutional review boards, or independent ethics committees. All studies complied with the guidelines of the Declaration of Helsinki and the International Conference on Harmonization Guidelines on Good Clinical Practice. Written informed consent was obtained from all participants before participation in the study. All studies were dose ranging and included a placebo-control group. The route of study drug administration was by SC injection in all protocols.

Bioanalytical methods

Human plasma drug concentrations were determined for each ASO using hybridization-based bioanalytical methods [45]. For GalNAc₃-conjugated 2'MOE ASOs, the assay quantitated full-length ASOs (including fully conjugated, partially conjugated with 1, 2, or 3-sugar deletions, and unconjugated ASO). All plasma sample analyses were performed based on the principles and requirements described in 21 Code of Federal Regulations Part 58.

Pharmacokinetic analysis

Noncompartmental analysis methods were used for pharmacokinetic characterization of the plasma concentration data (Phoenix WinNonlin v.6 or higher; Certara, L.P., Cary, NC). Plasma pharmacokinetic parameters reported include peak plasma concentration ($C_{\max}$) and time to $C_{\max}$ ($T_{\max}$), AUC_{0-24h} , clearance at steady state (CL_{ss}/F), and apparent terminal elimination half-life ($t_{1/2\lambda z}$).

Dose-response analysis

The relationship between each pharmacodynamic biomarker response (ie, the individual plasma target protein levels) and dose in human following multiple dose treatments (typically 2 weeks after the last treatment) was analyzed with an inhibitory $E_{\max}$ model using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA) by the following equation: $E = 100 / (1 + 10^{(\log X - \log ED_{50})})$, where E is the measured response (% baseline), X is the weekly dose, and

ED_{50} is the weekly dose that produced 50% of maximum drug-induced effect.

Safety assessments

Samples were collected before dosing for standard clinical laboratory tests and collected at several time points within a 24-h period after SC dose administration for coagulation tests and complement split products. Data were imported from individual study data sets into one SAS data set for each laboratory test [46].

Injection site reactions (ISRs) were defined as injection site erythema, injection site swelling, injection site pruritus, injection site pain or tenderness that started the day of SC injection, and persisted (start to stop) for 2 days or more. Flu-like symptoms were defined as either (1) influenza-like illness or (2) pyrexia, feeling hot or body temperature increased, plus at least two of the following: chills, myalgia, or arthralgia that started on the day of injection or the next day.

Statistics

Evaluable subjects were those who received at least one dose of study drug. Data are presented by the incidence of events and descriptive summary statistics of laboratory test results. All study data were included for analysis of the incidence of events, except where noted. The baseline was defined as the last nonmissing value before the first dose. An event was defined as data falling outside the normal range or reaching the specified threshold, as defined by protocol stopping rules, standard reporting, or Grade 3 criteria provided by the Food and Drug Administration in Guidance to Industry for healthy adults and adolescents [47].

The over-time analysis of laboratory test results included all study data up to last visit in the single dose regimen cohort, and up to 10 days after the last dose in the multidose regimen cohort. The lower-limit-of-normal and upper-limit-of-normal (ULN) displayed in the mean results over time figures represent the median values (Supplementary Table S1). If there was no reference range available, then the range was calculated as the (mean $\pm 2 \times$ SD) of the baseline values in the data set.

A meta-analysis using subject-level data was performed to compare ASO-treated dose groups to placebo group on the multidose regimen test results during the treatment period, defined as the period from first dose to up to 10 days after last dose. The endpoints evaluated were the absolute change from baseline. The data were compared between GalNAc₃-conjugated 2'MOE ASO dose groups and placebo using an analysis of covariance model with the dose group and trial as factors and baseline value as a covariate.

Results

To compare the behaviors of the parent PS 2'MOE ASOs with the GalNAc₃-conjugated drugs, we performed similar randomized placebo-controlled dose-ranging phase 1 studies in normal volunteers. Single doses of 5–120 mg and multiple doses of 10–120 mg were evaluated in these studies. The multiple dose regimens included six weekly SC doses (Supplementary Table S2), and we also evaluated monthly

doses for the GalNAC₃-conjugated 2'MOE ASOs. Because GalNAC₃-conjugated PS-modified 2'MOE ASOs are substantially more potent for liver targets, they were administered at lower doses than the parent PS-modified 2'MOE ASOs.

Comparison of the pharmacokinetic properties of PS 2'MOE parents with the GalNAC₃ conjugates

Figure 1 gives a schematic of the primary mechanism of entry into hepatocytes for GalNAC₃-conjugated 2'MOE

FIG. 1. GalNAC₃-conjugated PS 2'MOE ASOs demonstrate an increased fraction of total liver distribution to hepatocytes compared with parent 2'MOE ASOs. **(a)** Targeted hepatocyte delivery by the asialoglycoprotein receptor, and **(b)** estimation of relative exposure at therapeutic doses. 2'MOE, 2'-O-methoxyethyl; ASO, antisense oligonucleotide; PS, phosphorothioate.

TABLE 1. EVALUATION OF EIGHT UNIQUE GALNAC₃-CONJUGATED PHOSPHOROTHIOATE 2'-O-METHOXYETHYL ANTISENSE OLIGONUCLEOTIDES

Molecular target ^a	ID	Sequence (5'-3')	Length	Design	Phase 1 HV-RCT, n		
					Placebo	Active	Total
<i>ApoC3</i>	678354	L-AGCTTCTTGTCCAGCTTTAT	20	5-10-5 MOE (PS)	18	49	67
<i>LPA</i>	681257	L-TGCTCCGTTGGTGTCTGTC	20	5-10-5 MOE (PO/PS)	13	45	58
<i>CFB</i>	696844	L-ATCCCACGCCCCTGTCCAGC	20	5-10-5 MOE (PS)	12	42	54
<i>ANGPTL3</i>	703802	L-GGACATTGCCAGTAATCGCA	20	5-10-5 MOE (PO/PS)	12	36	48
<i>HBV S</i>	712408	L-GCAGAGGTGAAGCGAAGTGC	20	5-10-5 MOE (PS)	14	42	56
<i>KLKB1^b</i>	721744	L-TGCAAGTCTCTTGGCAAACA	20	5-10-5 MOE (PO/PS)	8	24	32
<i>AGT</i>	757456	L-CACAAACAAGCTGGTCGGTT	20	5-10-5 MOE (PS)	12	29	41
<i>GHR</i>	766720	L-CCACCTTTGGGTGAATAGCA	20	5-10-5 MOE (PO/PS)	9	27	36
Total					98	294	392

^aMolecular target indicates the RNA target, *e.g.* mRNA or pre-mRNA. Symbols and nomenclature are based on HUGO standards.

^bData not included in primary integrated analyses (monthly dose ranging pharmacokinetics and pharmacodynamics only).

AGT, angiotensinogen; ANGPTL3, angiopoietin-like 3; Apo, apolipoprotein; APOC3, apolipoprotein C3 (apoCIII); CFB, complement factor B (FB); FB, factor B; GHR, growth hormone receptor; HBV S, hepatitis B virus surface antigen; HV-RCT, healthy volunteer randomized controlled trial; KLKB1, kallikrein B1 (PKK, prekallikrein); L, GalNac₃; LPA, lipoprotein (a) [apo(a)]; PO, phosphodiester; PS, phosphorothioate.

ASOs and the estimated exposure compared with the parent. We have shown that liver concentrations can be estimated by plasma trough concentrations by combining these calculations with liver subfractionation studies conducted in animals to estimate total liver and hepatocyte/nonhepatocyte concentrations [39,48,49]. The lower doses used for GalNac₃-conjugated PS-modified 2'MOE ASOs result in lower peak plasma concentrations (C_{max}) and plasma concentration area under the curves (AUCs). The fraction of dose distributed to the liver of GalNac₃-conjugated PS 2'MOE ASOs is similar to the parent PS-modified 2'MOE ASOs; however, ~80% of the total drug in the liver is delivered to hepatocytes for the GalNac₃ conjugates, in contrast to ~12% with the parent ASOs. This is the reason GalNac₃-conjugated ASOs are so much more potent for hepatocyte targets than the parent ASOs. In addition, GalNac₃-conjugated 2'MOE ASOs achieve an equivalent potency at hepatocyte concentrations that are twofold to threefold lower than that of the parent. Therefore, in addition to enhancing

total delivery to hepatocytes, more of the ASO is internalized in hepatocyte through "productive" pathways, that is, pathways that deliver ASOs to sites within the cell where target RNAs can be hybridized with the ASO. This has been shown conclusively *in vitro* and in animals [39,44,48,49].

Table 1 gives the GalNac₃-conjugated PS-modified 2'MOE ASOs for which phase 1 data were available for safety and tolerability assessments. Directly assayable plasma analytes were available to assess pharmacodynamic effects for four GalNac₃ conjugates, ANGPTL3-L, Apo(a)-L, ApoCIII-L, and FB-L, with data available to support a direct comparison of the properties of the GalNac₃ versions with the parent molecules for three conjugates, ANGPTL3, Apo(a), and ApoCIII (volanesorsen). Thus, we focused on these ASOs for pharmacokinetic and pharmacodynamic comparisons.

As given in Table 2, the elimination half-lives of a representative parent PS-modified 2'MOE ASOs and the respective GalNac₃ conjugate were similar. Of course, the C_{max}

TABLE 2. PHARMACOKINETIC PROPERTIES OF A PARENT AND GALNAC₃-CONJUGATED PHOSPHOROTHIOATE 2'-O-METHOXYETHYL ANTISENSE OLIGONUCLEOTIDE TARGETING APO(A)

	Dose, mg	Study day	N	C_{max} , $\mu\text{g/mL}$	T_{max} , h	AUC_{0-24h} , $\mu\text{g} \times \text{h/mL}$	CL_{ss}/F , L/h	$t_{1/2\lambda z}$, days
Parent PS 2'MOE ASO	100	1	8	2.90 $\pm$ 0.692	3.5 (2, 6)	29.8 $\pm$ 6.62	—	—
		22	8	3.08 $\pm$ 0.969	3 (3, 6)	31.0 $\pm$ 9.51	2.37 $\pm$ 0.702	24.5 $\pm$ 4.39
	200	1	9	7.47 $\pm$ 2.84	3 (1.5, 4)	76.5 $\pm$ 22.7	—	—
		22	7	7.05 $\pm$ 2.01	3 (1.5, 6)	72.5 $\pm$ 25.1	1.85 $\pm$ 0.616	21.5 $\pm$ 7.06
	300	1	8	12.2 $\pm$ 4.14	4 (3, 8)	138 $\pm$ 27.8	—	—
		22	7	9.22 $\pm$ 3.94	4 (3, 6)	105 $\pm$ 29.1	1.68 $\pm$ 0.328	21.6 $\pm$ 9.19
GalNac ₃ conjugate	10	1	8	0.0640 $\pm$ 0.0216	2 (1, 4)	0.560 $\pm$ 0.168	—	—
		22	8	0.0599 $\pm$ 0.0252	3.5 (1, 4)	0.563 $\pm$ 0.241	14.8 $\pm$ 3.83	42.1 $\pm$ 38.8
	20	1	8	0.149 $\pm$ 0.0423	2.26 (1, 8)	1.18 $\pm$ 0.293	—	—
		22	8	0.154 $\pm$ 0.105	2.5 (1, 4)	1.13 $\pm$ 0.254	14.9 $\pm$ 3.17	29.4 $\pm$ 7.86
	40	1	8	0.177 $\pm$ 0.062	2.01 (1, 8)	1.98 $\pm$ 0.765	—	—
		22	8	0.208 $\pm$ 0.0797	1 (1, 3)	1.81 $\pm$ 0.547	15.9 $\pm$ 4.4	25.7 $\pm$ 5.65

Values are presented as mean $\pm$ SD, except T_{max} , which is presented as median (minimum, maximum). CL_{ss}/F is the plasma clearance at steady state after subcutaneous administration. CL_{ss}/F was calculated by actual dose/ $AUC_{0-\tau}$, where $AUC_{0-\tau}$ refers to the area under the plasma concentration-time curve (AUC) from time 0 to dosing interval τ following the last dose and τ = 168 hours.

2'MOE, 2'-O-methoxyethyl; ASO, antisense oligonucleotide; AUC, area under the curve; CL_{ss}/F , clearance at steady state; C_{max} , peak plasma concentration; T_{max} , time to C_{max} ; SD, standard deviation; $t_{1/2\lambda z}$, terminal elimination half-life.

FIG. 2. Pharmacokinetic profile after multiple SC doses of GalNAC₃ conjugate versus parent PS 2'MOE ASO. Comparison of 0- to 24-h plasma concentration–time profiles, (a) linear scale, and (b) semi-log scale. Data shown are the mean and error bars represent the standard deviation. SC, subcutaneous.

and AUC values were lower for the GalNAC₃ conjugates, reflecting the lower dose, and the times to peak plasma concentrations (T_{max}) were similar (as given in Fig. 2). However, distribution from plasma for the GalNAC₃ version was more rapid as shown by the approximately fivefold higher rate of clearance from plasma (CL_{ss}/F). The more rapid distribution phase may suggest more rapid extraction from plasma by tissues, but this explanation remains speculative. The extent of plasma protein binding by the GalNAC₃ conjugates was similar to the parent 2'MOE ASOs in all species tested (mouse, 94%–99%; monkey, 97%–99%; humans, 96%–99%). The other pairs of PS-modified 2'MOE ASOs studied behaved similarly (data not shown).

Pharmacodynamics

The most striking difference between the parent and GalNAC₃ versions is potency (Fig. 3). The ED_{50} s for the parents range from 120 to 210 mg/week, whereas the ED_{50} s for the GalNAC₃ versions range from 4 to 10 mg/week. The ED_{50} s for target reduction for nearly all the PS 2'MOE ASOs are in this range. The consistency of performance of PS 2'MOE ASOs and the GalNAC₃ versions is remarkable and consistent in species ranging from mouse, NHPs, to humans. This consistency in pharmacokinetics and pharmacodynamics supports many drug development efficiencies. To compare the pharmacokinetic properties

FIG. 3. Increased potency observed with GalNAC₃-conjugated PS 2'MOE ASOs in phase 1 healthy volunteer studies. Data shown are the mean, error bars represent the standard error, and the lines are fit to the mean data.

FIG. 4. Pharmacokinetic and pharmacodynamic profile of GalNAc₃-conjugated PS 2'MOE ASO in humans after monthly SC doses on study days 1, 29, 57, and 85. **(a)** Mean plasma drug concentration-time profiles with intensive pharmacokinetic sampling on study days 1 and 85, predose, and ~0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48-h after the respective first and last SC injections. **(b)** Mean percent change from baseline over time in plasma prekallikrein levels in subjects who received monthly doses of PKK-L compared with pooled placebo-treated subjects. Blue arrowheads indicate dose days. PKK, prekallikrein.

TABLE 3. PHARMACOKINETIC PROPERTIES OF A GALNAc₃-CONJUGATED PHOSPHOROTHIOATE 2'-O-METHOXYETHYL ANTISENSE OLIGONUCLEOTIDE TARGETING PREKALLIKREIN

Dose, mg	Study day	N	C_{max} , µg/mL	T_{max} , h	AUC_{0-24h} , µg·h/mL	AUC_{0-168h} , µg·h/mL	AUC , µg·h/mL	CL/F , L/h	$t_{1/2\lambda_z}$, days
20	1	6	0.093 ± 0.035	1.5 (1.0, 4.0)	0.766 ± 0.304	0.810 ± 0.326	—	—	—
	85	6	0.145 ± 0.109	1.0 (1.0, 2.0)	0.776 ± 0.190	0.872 ± 0.203	1.01 ± 0.221	20.1 ± 4.8	21.1 ± 19.6
40	1	6	0.209 ± 0.063	1.0 (1.0, 2.0)	1.65 ± 0.478	1.78 ± 0.513	—	—	—
	85	6	0.230 ± 0.130	1.8 (1.0, 6.0)	1.57 ± 0.528	1.78 ± 0.586	2.18 ± 0.801	21.0 ± 0.9	38.1 ± 15.8
60	1	6	0.458 ± 0.099	3.0 (3.0, 4.0)	3.66 ± 0.787	3.90 ± 0.825	—	—	—
	85	6	0.779 ± 0.435	2.5 (0.5, 8.0)	4.82 ± 1.57	5.10 ± 1.59	5.72 ± 1.72	11.3 ± 3.3	30.8 ± 3.1
80	1	6	0.623 ± 0.195	1.0 (1.0, 4.0)	4.28 ± 0.842	4.56 ± 0.826	—	—	—
	85	6	0.807 ± 0.431	2.5 (1.5, 6.0)	5.05 ± 1.25	5.47 ± 1.31	6.10 ± 1.50	13.8 ± 3.3	NA

Values are presented as the mean ± SD, except T_{max} , which is presented as median (minimum, maximum). CL_{ss}/F is the plasma clearance at steady state after subcutaneous administration. CL_{ss}/F was calculated by actual dose/ $AUC_{0-\tau}$, where $AUC_{0-\tau}$ refers to the area under the plasma concentration-time curve (AUC) from time 0 to dosing interval τ following the last dose and $\tau=672$ hours.

NA, not available.

TABLE 4. DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF THE WEEKLY MULTI-DOSE REGIMEN COHORT (N=157)

	Dose categories, mg/week						
	Placebo	Total ASO	>0–10	>10–20	>20–40	>40–60	>60
N	36	121	32	38	33	12	6
Sex, n (%)							
Male	26 (72.2%)	95 (78.5%)	25 (78.1%)	25 (65.8%)	29 (87.9%)	10 (83.3%)	6 (100.0%)
Female	10 (27.8%)	26 (21.5%)	7 (21.9%)	13 (34.2%)	4 (12.1%)	2 (16.7%)	0 (0.0%)
Age, year							
Mean (SD, SEM)	48 (12, 2)	48 (11, 1)	50 (10, 2)	49 (11, 2)	47 (12, 2)	48 (12, 3)	39 (12, 5)
Median (P25, P75)	51 (39, 57)	50 (40, 57)	52 (44, 58)	52 (44, 57)	49 (39, 60)	50 (45, 58)	33 (30, 53)
Min, Max	17, 64	23, 65	28, 64	25, 65	23, 65	24, 62	27, 55
Race, n (%)							
Asian	6 (16.7%)	15 (12.4%)	2 (6.3%)	6 (15.8%)	4 (12.1%)	3 (25.0%)	0 (0.0%)
Black	4 (11.1%)	12 (9.9%)	5 (15.6%)	3 (7.9%)	4 (12.1%)	0 (0.0%)	0 (0.0%)
White	23 (63.9%)	89 (73.6%)	24 (75.0%)	26 (68.4%)	25 (75.8%)	8 (66.7%)	6 (100.0%)
Other	3 (8.3%)	5 (4.1%)	1 (3.1%)	3 (7.9%)	0 (0.0%)	1 (8.3%)	0 (0.0%)
BMI, kg/m ²							
Mean (SD, SEM)	26.2 (3.5, 0.6)	26.7 (3.7, 0.3)	28.2 (3.5, 0.6)	25.9 (3.9, 0.6)	26.6 (3.6, 0.6)	26.3 (3.5, 1.0)	24.1 (2.2, 0.9)
Median (P25, P75)	25.7 (24.0, 29.1)	26.4 (23.7, 28.8)	27.5 (25.9, 30.9)	24.7 (23.4, 28.3)	26.5 (24.3, 28.3)	26.8 (24.5, 28.3)	23.6 (22.8, 25.2)
Min, Max	18.9, 33.2	19.7, 35.1	20.6, 35.1	20.4, 34.2	21.1, 34.1	19.7, 32.1	21.5, 27.9

BMI, body mass index; P25, 25th percentile; P75, 75th percentile; SD, standard deviation; SEM, standard error from the mean.

of the parent and GalNAc₃ versions at doses resulting in equivalent target reductions, Supplementary Fig. S1 compares the pharmacokinetics of the parent and GalNAc₃-conjugated 2'MOE ASO for apolipoprotein(a) at 300 mg versus 10 mg, respectively. These doses result in ~60% reduction of plasma Apo(a) levels. With the exception of a significantly lower C_{max}, the GalNAc₃ version behaved similarly to the parent. This was true for the other pairs of parent and GalNAc₃-conjugated 2'MOE ASOs (data not given).

Because of the substantial increase in potency conferred by GalNAc₃ conjugation for reducing RNA targets expressed in the hepatocyte, and the elimination half-lives from tissues for these agents range from 3 to 4 weeks, we also evaluated monthly administration of the GalNAc₃-conjugated 2'MOE ASOs. The main purposes of this exercise were to define monthly dose–response curves and to assess if the mid-dose trough level of analytes were reasonably maintained. The monthly doses behaved similarly to the comparable doses in the single-dose and multiple-dose weekly cohorts, and the target reductions were maintained between doses as predicted by the pharmacokinetic properties of these drugs (Fig. 4 and Table 3).

Safety

Integrated analysis of the safety data for the GalNAc₃-conjugated 2'MOE ASOs included laboratory tests for liver (alanine transaminase, aspartate transaminase, total bilirubin, alkaline phosphatase, and albumin), kidney (serum creatinine, blood urea nitrogen, calculated glomerular filtration rate, and urine total protein), hematology (platelets, absolute neutrophil count, lymphocytes, hemoglobin, and hematocrit), coagulation (activated partial thromboplastin time and prothrombin time) and complement activation (complement split products Bb and C5a).

The results from the multiple ascending weekly doses are given in the primary figures and tables (Figs. 5–9 and Tables 4 and 5) with the respective protocol-specified dose schedules given in Supplementary Table S2; and the results of single ascending doses in the supplementary material (Supplementary Figs. S2–S5 and Supplementary Tables S8 and S9).

The demographics of the subjects in the multidose cohort were as expected for normal volunteers (Table 4). As can be seen, there were no effects observed at any dose level on the mean values of any of the analytes measured (Figs. 5–7). To identify individuals who may have had excursions in any analyte, we show the incidences of data falling outside the normal range or reaching a specified threshold. Any abnormal value during treatment or follow-up is reported for liver, kidney, and hematology analytes (Table 5). No abnormal liver analytes above three times the ULN were observed in the 157 subjects studied. Two subjects displayed creatinine clearances <60 mL/min, one in the placebo group and one in the >10–20 mg/week group. The placebo subject entered the study with a creatinine clearance of 57 mL/min, received each of the four planned doses and the creatinine increased during treatment, but was still low and then returned to approximately the entry level at last observation, meeting the event criteria. The ASO-treated subject was a 57-year-old woman who at entry had a creatinine clearance of 63 mL/min and received each of the eight planned doses of study drug. The creatinine clearance decreased to 58 mL/min in week 1, meeting the event criteria, and was stable at that range. A single 55-year-old male subject in the >10–20 mg/week dose group, who received each of six planned doses, entered with a hemoglobin of 11.2 g/dL and declined to 10.2 g/dL in week 4.

To evaluate potential effects on platelets more closely, we constructed individual-subject spaghetti plots of platelet values for all drugs and all doses tested. No abnormal values were observed as given in Fig. 8 for each subject in the multidose regimen cohort (N=157) and Supplementary Fig. S5 for each subject in the single-dose regimen cohort (N=193). In addition to these results there was no effect on coagulation or evidence of complement activation relative to baseline during the 24-h period after the first dose in both the single- and multidose cohorts (Table 5 and Fig. 9). In short, there were no dose-related abnormalities in any parameter tested.

The tolerability of the GalNAc₃ 2'MOE ASOs was excellent. There were no discontinuations because of adverse events. No flu-like symptoms were reported, and the

FIG. 5. Mean laboratory measurements over time for assessment of liver function in the weekly multidose regimen cohort, (a) alanine transaminase, (b) aspartate transaminase, (c) total bilirubin, (d) alkaline phosphatase, and (e) albumin. Each data point represents data from at least 10 subjects and 3 GalNAc₃-conjugated 2'MOE ASOs during the treatment period. Gray dashed lines represent the median reference range values and yellow dashed lines indicate the event criteria. A tabulated summary of results is provided in Supplementary Table S3.

FIG. 6. Mean laboratory measurements over time for assessment of kidney function in the weekly multidose regimen cohort, (a) serum creatinine, (b) blood urea nitrogen, and (c) calculated glomerular filtration rate. Each data point represents data from at least 10 subjects and 3 GalNAC₃-conjugated 2'MOE ASOs during the treatment period. Gray dashed lines represent the median reference range values and yellow dashed lines indicate the event criteria. A tabulated summary of results is provided in Supplementary Table S4.

incidence of mild injection site reactions was only 3%. There were no moderate or severe ISRs. With the PS 2'MOE type drugs, the incidence of ISRs ranged from 8% to 48% in similar phase 1 studies [36].

Discussion

GalNAC₃ conjugation is the first example of targeted delivery of PS 2'MOE ASOs and represents a significant advance for targets expressed in the liver. The mechanism of targeting does not increase total liver concentrations of the ASOs. Rather, the ligand results in a greater fraction of total

liver ASO to be delivered to the hepatocyte without significant changes in the elimination of the ASO [29,39,49]. Since at the low dose employed for GalNAC₃ ASOs the total hepatocyte concentration does not exceed the concentrations observed for the parent drugs [39], two important conclusions were obtained. First in humans, as has been demonstrated in animal model studies [39], the GalNAC₃ moiety must result in a higher fraction of 2'MOE ASO delivered to hepatocytes being delivered productively. The second conclusion is also important: For PS 2'MOE ASOs, GalNAC₃ conjugation does not increase the total hepatocyte exposure at therapeutic doses arguing that hepatocyte safety should be as attractive as

FIG. 7. Mean laboratory measurements over time for assessment of hematology in the weekly multidose regimen cohort, **(a)** platelets, **(b)** hemoglobin, **(c)** hematocrit, **(d)** lymphocyte count, and **(e)** absolute neutrophil count. Each data point represents data from at least 10 subjects and 3 GalNAc₃-conjugated 2'MOE ASOs during the treatment period. Gray dashed lines represent the median reference range values and yellow dashed lines indicate the event criteria. A tabulated summary of results is provided in Supplementary Table S5.

FIG. 8. Individual subject assessment of platelet counts over time in the weekly multidose regimen cohort by dose level, (a) Placebo, (b) >0–10 mg, (c) >10–20 mg, (d) >20–40 mg, (e) >40–60 mg, and (f) >60 mg. Gray dashed lines represent the median reference range values and yellow dashed lines indicate the event criteria.

FIG. 9. Mean laboratory measurements of coagulation and complement activation over the 24-h period postdose 1 in single and weekly multidose regimen cohorts, (a) activated partial thromboplastin time, (b) prothrombin time, (c) complement split product Bb, and (d) complement split product C5a. Each data point represents data from at least 10 subjects and 3 GalNAc₃-conjugated 2'MOE ASOs. Gray dashed lines represent the median reference range values and yellow dashed lines indicate the event criteria. A tabulated summary of results is provided in Supplementary Tables S6 and S7.

TABLE 5. INCIDENCE OF ABNORMAL LABORATORY TEST RESULTS IN WEEKLY MULTIDOSE REGIMEN COHORT (N=157)

		<i>Dose categories, mg/week</i>						
<i>Event, n (%)</i>		<i>Placebo</i>	<i>Total ASO</i>	<i>>0–10</i>	<i>>10–20</i>	<i>>20–40</i>	<i>>40–60</i>	<i>>60</i>
Liver	ALT, <i>n</i>	36	121	32	38	33	12	6
	>3×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	>5×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	AST, <i>n</i>	36	121	32	38	33	12	6
	>3×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	>5×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Total bilirubin, <i>n</i>	36	121	32	38	33	12	6
	>2×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	>2×ULN AND ALT >3×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Alkaline phosphatase, <i>n</i>	36	121	32	38	33	12	6
Kidney	>3×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Albumin, <i>n</i>	36	121	32	38	33	12	6
	<2.5 g/dL, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Serum creatinine, <i>n</i>	36	121	32	38	33	12	6
	≥0.3 mg/dL increase from BSLN AND ≥1.4×BSLN, <i>n (%)</i>	0 (0.0)	1 (0.8)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	>2.1 mg/dL, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	BUN, <i>n</i>	36	121	32	38	33	12	6
	>31 mg/dL, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	eGFR, <i>n</i>	36	121	32	38	33	12	6
	<60 mL/min per 1.73 m ² , <i>n (%)</i>	1 (2.8)	1 (0.8)	0 (0.0)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)
Hematology	<30 mL/min per 1.73 m ² , <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Urine protein, ^a <i>n</i>	36	121	32	38	33	12	6
	≥2+ (100 mg/dL), <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	≥3+ (200 mg/dL), <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Platelets, <i>n</i>	36	121	32	38	33	12	6
	<100 K/mm ³ , <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	<75 K/mm ³ , <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Hemoglobin, <i>n</i>	36	121	32	38	33	12	6
	M < 10.5 g/dL; F < 9.5 g/dL, <i>n (%)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)
	Hematocrit, <i>n</i>	36	121	32	38	33	12	6
Coagulation	<0.85×BSLN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	<30% (absolute value), <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Lymphocytes, <i>n</i>	36	120	32	37	33	12	6
	<0.5 K/mm ³ , <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Abs. neutrophil count, <i>n</i>	36	121	32	38	33	12	6
	<1.0 K/mm ³ , <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	APTT, <i>n</i>	36	121	32	38	33	12	6
	>1.4×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	PT, <i>n</i>	36	121	32	38	33	12	6
	>1.2×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Complement	Bb, <i>n</i>	36	121	32	38	33	12	6
	>2×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	C5a, <i>n</i>	30	97	20	26	33	12	6
	>2×ULN, or BSLN if >ULN, <i>n (%)</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Incidence of events is based on confirmed test results for liver, kidney, and hematology parameters during the study period. The incidence of coagulation and complement activation events was determined by a single observation. A confirmed event was defined as a consecutive abnormal laboratory value on a different day. If there was no consecutive test to confirm, then the initial observation was presumed confirmed. If there were multiple values on the same day but different time, the worst value was used. ALT and AST events were confirmed by two consecutive measurements at least 7 days apart with all values between the initial and subsequent test also above the specified threshold.

^aUrine protein was determined by dipstick.

ALT, alanine transaminase; APTT, activated partial thromboplastin time; AST, aspartate transaminase; BSLN, baseline; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ULN, upper-limit-of-normal.

the safety of the unconjugated ASOs. This is supported by the absence of liver signals. The reduced doses that can be used for GalNAc₃-conjugated 2'MOE ASOs means that peak plasma concentration-related adverse events are likely to be reduced. Lower doses also enhance tolerability and support less frequent than weekly dosing.

The success of GalNAc₃ conjugation has stimulated broader efforts to identify ligands that enhance delivery of ASOs to other organs. We and our colleagues at AstraZeneca have reported that conjugation of Glp1 to PS ASOs dramatically increased delivery to the pancreatic islet cells resulting for the first time in robust activity against pancreatic targets [50]. Broader research on targeting ligands may enhance delivery to other organs in due course.

Acknowledgments

The authors thank Tracy Reigle for graphics support; Ekaette Mbong, PhD and Lisa Hannan, PhD for technical support; Eugene Schneider, MD, Michael L. McCaleb, PhD, Brett P. Monia, PhD, Sanjay Bhanot, MD, PhD, and the clinical development project teams for the individual phase 1 trials; John Su, PhD, and the biometrics team for support on the integrated safety database.

Author Disclosure Statement

All authors are employees of Ionis Pharmaceuticals.

Supplementary Material

Supplementary Figure1
Supplementary Figure2
Supplementary Figure3
Supplementary Figure4
Supplementary Figure5
Supplementary Table1
Supplementary Table2
Supplementary Table3
Supplementary Table4
Supplementary Table5
Supplementary Table6
Supplementary Table7
Supplementary Table8
Supplementary Table9

References

1. Crooke ST, JL Witzum, CF Bennett and BF Baker. (2018). RNA-targeted therapeutics. *Cell Metab* 27:714–739.
2. Crooke ST, ed. (2008). *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. CRC Press, Boca Raton, FL.
3. Bennett CF, BF Baker, N Pham, E Swayze and RS Geary. (2017). Pharmacology of antisense drugs. *Annu Rev Pharmacol Toxicol* 57:81–105.
4. Monia BP, JF Johnston, DJ Ecker, MA Zounes, WF Lima and SM Freier. (1992). Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. *J Biol Chem* 267:19954–19962.
5. Crooke ST, T Vickers, W Lima and H Wu. (2008). Mechanisms of antisense drug action, an introduction. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 3–46.
6. Swayze EE and B Bhat. (2008). The medicinal chemistry of oligonucleotides. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, pp 143–182.
7. Levin AA, RZ Yu and RS Geary. (2008). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 183–215.
8. Iversen PL. (2008). Morpholinos. In: *Antisense Drug Technology: Principles, Strategies, and Applications*. Crooke ST, ed. CRC Press, Boca Raton, pp 565–582.
9. Shen W, CL De Hoyos, H Sun, TA Vickers, XH Liang and ST Crooke. (2018). Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. *Nucleic Acids Res* 46:2204–2217.
10. Crooke ST, S Wang, TA Vickers, W Shen and XH Liang. (2017). Cellular uptake and trafficking of antisense oligonucleotides. *Nat Biotechnol* 35:230–237.
11. Rajeev KG, JK Nair, M Jayaraman, K Charisse, N Taneja, J O'Shea, JL Willoughby, K Yucius, T Nguyen, *et al.* (2015). Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. *Chembiochem* 16: 903–908.
12. Manoharan M and KG Rajeev. (2008). Utilizing chemistry to harness RNA interference pathways for therapeutics: Chemically modified siRNA and Antagomirs. In: *Antisense Drug Technology: Principles, Strategies, and Applications*. Crooke ST, ed. CRC Press, Boca Raton, pp 437–464.
13. Yu D, H Pendergraff, J Liu, HB Kordasiewicz, DW Cleveland, EE Swayze, WF Lima, ST Crooke, TP Prakash and DR Corey. (2012). Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. *Cell* 150:895–908.
14. Duell PB, RD Santos, BA Kirwan, JL Witzum, S Tsimikas and JJP Kastelein. (2016). Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. *J Clin Lipidol* 10:1011–1021.
15. Gaudet D, A Digenio, VJ Alexander, M Arca, AF Jones, E Stroes, J Bergeron, F Civeira, L Hemphill, *et al.* (2017). The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). *J Clin Lipidol* 11:814–815.
16. Benson MD, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, AK Wang, V Planté-Bordeneuve, FA Barroso, G Merlini, *et al.* (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med* 379: 22–31.
17. Finkel RS, E Mercuri, BT Darras, AM Connolly, NL Kuntz, J Kirschner, CA Chiriboga, K Saito, L Servais, *et al.* (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *N Engl J Med* 377:1723–1732.
18. Mercuri E, BT Darras, CA Chiriboga, JW Day, C Campbell, AM Connolly, ST Iannaccone, J Kirschner, NL Kuntz, *et al.* (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. *N Engl J Med* 378:625–635.
19. Mercuri E, R Finkel, J Kirschner, C Chiriboga, N Kuntz, P Sun, S Gheuens, C Bennett, E Schneider and W Farwell.

- (2017). Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. *Neuromuscul Disord* 27:S210.
20. Lima W, H Wu and ST Crooke. (2008). The RNase H mechanism. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 47–74.
 21. Liang XH, W Shen, H Sun, MT Migawa, TA Vickers and ST Crooke. (2016). Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. *Nat Biotechnol* 34:875–880.
 22. Liang XH, H Sun, W Shen and ST Crooke. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. *Nucleic Acids Res* 43:2927–2945.
 23. Geary RS, RZ Yu, A Siwkowski and AA Levin. (2008). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 305–326.
 24. Geary RS, D Norris, R Yu and CF Bennett. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv Drug Deliv Rev* 87:46–51.
 25. Donner AJ, TA Bell, S Greenlee, MJ Graham and RM Crooke. (2018). Characterization of the activity and distribution of a 2'-O-methoxyethyl-modified antisense oligonucleotide in models of acute and chronic kidney disease. *Nucleic Acid Ther* 28:297–306.
 26. Graham MJ, ST Crooke, DK Monteith, SR Cooper, KM Lemonidis, KK Stecker, MJ Martin and RM Crooke. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. *J Pharmacol Exp Ther* 286:447–458.
 27. Mullick AE, ST Yeh, MJ Graham, JA Engelhardt, TP Prakash and RM Crooke. (2017). Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. *Hypertension* 70:566–576.
 28. Geary RS, RZ Yu, T Watanabe, SP Henry, GE Hardee, A Chappell, J Matson, H Sasmor, L Cummins and AA Levin. (2003). Pharmacokinetics of a tumor necrosis factor- α phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. *Drug Metab Dispos* 31:1419–1428.
 29. Yu RZ, JS Grundy, SP Henry, TW Kim, DA Norris, J Burkey, Y Wang, A Vick and RS Geary. (2015). Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications. *Mol Ther Nucleic Acids* 4:e218.
 30. Yu RZ, TW Kim, A Hong, TA Watanabe, HJ Gaus and RS Geary. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. *Drug Metab Dispos* 35:460–468.
 31. Geary RS. (2009). Antisense oligonucleotide pharmacokinetics and metabolism. *Expert Opin Drug Metab Toxicol* 5: 381–391.
 32. Yu RZ, JS Grundy and RS Geary. (2013). Clinical pharmacokinetics of second generation antisense oligonucleotides. *Expert Opin Drug Metab Toxicol* 9:169–182.
 33. Yu RZ, RS Geary, JD Flaim, GC Riley, DL Tribble, AA vanVliet and MK Wedel. (2009). Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. *Clin Pharmacokinet* 48:39–50.
 34. Yu RZ, MS Warren, T Watanabe, B Nichols, M Jahic, J Huang, J Burkey, RS Geary, SP Henry and Y Wang. (2016). Lack of interactions between an antisense oligonucleotide with 2'-O-(2-methoxyethyl) modifications and major drug transporters. *Nucleic Acid Ther* 26:111–117.
 35. Bennett CF. (2008). Pharmacological properties of 2'-methoxyethyl-modified oligonucleotides. In: *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 273–303.
 36. Crooke ST, BF Baker, TJ Kwoh, W Cheng, DJ Schulz, S Xia, N Salgado, HH Bui, CE Hart, *et al.* (2016). Integrated safety assessment of 2'-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. *Mol Ther* 24:1771–1782.
 37. Crooke ST, BF Baker, NC Pham, SG Hughes, TJ Kwoh, D Cai, S Tsimikas, RS Geary and S Bhanot. (2018). The effects of 2'-O-methoxyethyl oligonucleotides on renal function in humans. *Nucleic Acid Ther* 28:10–22.
 38. Crooke ST, BF Baker, JL Witzum, TJ Kwoh, NC Pham, N Salgado, BW McEvoy, W Cheng, SG Hughes, S Bhanot and RS Geary. (2017). The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. *Nucleic Acid Ther* 27:121–129.
 39. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chappell, K Schmidt, C Zhao, M Aghajan, *et al.* (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. *Nucleic Acids Res* 42: 8796–8807.
 40. Viney NJ, JC van Capelleveen, RS Geary, S Xia, JA Tami, RZ Yu, SM Marcovina, SG Hughes, MJ Graham, *et al.* (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet* 388:2239–2253.
 41. Graham MJ, RG Lee, TA Brandt, LJ Tai, W Fu, R Peralta, R Yu, E Hurh, E Paz, *et al.* (2017). Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. *N Engl J Med* 377:222–232.
 42. Kinberger GA, TP Prakash, J Yu, G Vasquez, A Low, A Chappell, K Schmidt, HM Murray, H Gaus, EE Swayze and PP Seth. (2016). Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. *Bioorg Med Chem Lett* 26:3690–3693.
 43. Østergaard ME, J Yu, GA Kinberger, WB Wan, MT Migawa, G Vasquez, K Schmidt, HJ Gaus, HM Murray, *et al.* (2015). Efficient synthesis and biological evaluation of 5'-GalNAc conjugated antisense oligonucleotides. *Bioconjug Chem* 26:1451–1455.
 44. Miller CM, M Tanowitz, AJ Donner, TP Prakash, EE Swayze, EN Harris and PP Seth. (2018). Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. *Nucleic Acid Ther* 28:119–127.
 45. Yu RZ, B Baker, A Chappell, RS Geary, E Cheung and AA Levin. (2002). Development of an ultrasensitive

- noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. *Anal Biochem* 304:19–25.
46. Smith DJ, D Schulz, G Kloss and W Weng. (2010). Considerations for building an integrated safety database using SAS. www.lexjansen.com/pharmasug/2010/AD/AD15.pdf accessed August 24, 2018.
 47. FDA. (2007). US Food and Drug Administration Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007), www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977
 48. Yu RZ, MJ Graham, N Post, S Riney, T Zanardi, S Hall, J Burkey, CS Shemesh, TP Prakash, *et al.* (2016). Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. *Mol Ther Nucleic Acids* 5:e317.
 49. Yu RZ, R Gunawan, N Post, T Zanardi, S Hall, J Burkey, TW Kim, MJ Graham, TP Prakash, *et al.* (2016). Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys. *Nucleic Acid Ther* 26:372–380.
 50. Ämmälä C, I Ahlstedt, E-M Andersson, P Andersson, E Cavallin, W Drury, G Hung, R Jansson-Löfmark, C Johansson, *et al.* (2017). The GLP1 receptor as a homing beacon for targeted delivery to pancreatic β -cells: quantitating tissue selective productive uptake of antisense oligonucleotides. *Diabetes* 66:A568.

Address correspondence to:
 Stanley T. Crooke, MD, PhD
 Ionis Pharmaceuticals, Inc.
 2855 Gazelle Court
 Carlsbad, CA 92011

E-mail: scrooke@ionisph.com

Received for publication September 19, 2018; accepted after revision November 12, 2018.